AU2006228296B2 - New pharmaceutical compositions useful in the treatment of Parkinson's disease - Google Patents

New pharmaceutical compositions useful in the treatment of Parkinson's disease Download PDF

Info

Publication number
AU2006228296B2
AU2006228296B2 AU2006228296A AU2006228296A AU2006228296B2 AU 2006228296 B2 AU2006228296 B2 AU 2006228296B2 AU 2006228296 A AU2006228296 A AU 2006228296A AU 2006228296 A AU2006228296 A AU 2006228296A AU 2006228296 B2 AU2006228296 B2 AU 2006228296B2
Authority
AU
Australia
Prior art keywords
composition
carrier particles
particles
acid
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006228296A
Other languages
English (en)
Other versions
AU2006228296A1 (en
Inventor
Thomas Lundqvist
Anders Pettersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexo AB
Original Assignee
Orexo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo AB filed Critical Orexo AB
Publication of AU2006228296A1 publication Critical patent/AU2006228296A1/en
Application granted granted Critical
Publication of AU2006228296B2 publication Critical patent/AU2006228296B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006228296A 2005-03-28 2006-03-28 New pharmaceutical compositions useful in the treatment of Parkinson's disease Ceased AU2006228296B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66537605P 2005-03-28 2005-03-28
US60/665,376 2005-03-28
PCT/GB2006/001132 WO2006103417A1 (en) 2005-03-28 2006-03-28 New pharmaceutical compositions useful in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
AU2006228296A1 AU2006228296A1 (en) 2006-10-05
AU2006228296B2 true AU2006228296B2 (en) 2011-08-04

Family

ID=34956744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006228296A Ceased AU2006228296B2 (en) 2005-03-28 2006-03-28 New pharmaceutical compositions useful in the treatment of Parkinson's disease

Country Status (13)

Country Link
US (1) US20080193526A1 (OSRAM)
EP (1) EP1863455A1 (OSRAM)
JP (1) JP2008534563A (OSRAM)
KR (1) KR20070114734A (OSRAM)
CN (1) CN101141949B (OSRAM)
AU (1) AU2006228296B2 (OSRAM)
CA (1) CA2599384A1 (OSRAM)
IL (1) IL185300A0 (OSRAM)
MX (1) MX2007011976A (OSRAM)
NO (1) NO20074199L (OSRAM)
NZ (1) NZ560826A (OSRAM)
RU (1) RU2440100C2 (OSRAM)
WO (1) WO2006103417A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
AU2008343787B2 (en) * 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2014186410A1 (en) 2013-05-13 2014-11-20 NeuOra Microceuticals, LLC Long lasting breath mint
KR101850479B1 (ko) 2015-07-22 2018-05-30 (주)듀켐바이오 [18F]플루오로-도파의 중성 pH 안정화 방법
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067004A1 (en) * 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5414167B1 (OSRAM) * 1970-12-28 1979-06-05
SE8800080L (sv) * 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
HU209564B (en) * 1991-01-30 1994-07-28 Egyt Gyogyszervegyeszeti Gyar Process for producing rapide tablets containing levodopa and carbidopa
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067004A1 (en) * 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition

Also Published As

Publication number Publication date
RU2007139826A (ru) 2009-05-10
NZ560826A (en) 2009-06-26
US20080193526A1 (en) 2008-08-14
MX2007011976A (es) 2007-12-07
KR20070114734A (ko) 2007-12-04
JP2008534563A (ja) 2008-08-28
WO2006103417A1 (en) 2006-10-05
EP1863455A1 (en) 2007-12-12
IL185300A0 (en) 2008-02-09
NO20074199L (no) 2007-11-21
CA2599384A1 (en) 2006-10-05
CN101141949B (zh) 2010-12-08
AU2006228296A1 (en) 2006-10-05
CN101141949A (zh) 2008-03-12
RU2440100C2 (ru) 2012-01-20

Similar Documents

Publication Publication Date Title
US20080248110A1 (en) Pharmaceutical Compositions Useful in the Treatment of Pain
JP2001058944A (ja) 速崩壊性固形製剤
BG107193A (bg) Ефервесцентни гранули и методи за тяхното получаване
US20090232898A1 (en) Pharmaceutical Compositions Useful in the Treatment of Migraine
CA2496110A1 (en) Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets
EP1539173A1 (en) Fast dissolving and taste masked oral dosage form comprising sildenafil
US20120277261A1 (en) Pharmaceutical formulations useful in the treatment of insomnia
US20080193526A1 (en) Pharmaceutical Compositions Useful in the Treatment of Pain
US9782396B2 (en) Alfentanil composition for the treatment of acute pain
JP2006070046A (ja) 速崩壊性固形製剤
AU2006228297A1 (en) New pharmaceutical compositions useful in the treatment of pain

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired